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Abstract: Oncolytic viruses provide a biologically multi-faceted treatment option for patients who
cannot be cured with currently available treatment options. We constructed an oncolytic adenovirus,
TILT-123, to support T-cell therapies and immune checkpoint inhibitors in solid tumors. Adenoviruses
are immunogenic by nature, are easy to produce in large quantities, and can carry relatively large
transgenes. They are the most commonly used gene therapy vectors and are well tolerated in
patients. TILT-123 expresses two potent cytokines, tumor necrosis factor alpha and interleukin-2,
to stimulate especially the T-cell compartment in the tumor microenvironment. Before entering
clinical studies, the safety and biodistribution of TILT-123 was studied in Syrian hamsters and in
mice. The results show that TILT-123 is safe in animals as monotherapy and in combination with an
immune checkpoint inhibitor anti-PD-1. The virus treatment induces acute changes in circulating
immune cell compartments, but the levels return to normal by the middle of the treatment period.
The virus is rapidly cleared from healthy tissues, and it does not cause damage to vital organs. The
results support the initiation of a phase 1 dose-escalation trial, where melanoma patients receiving a
tumor-infiltrating lymphocyte therapy are treated with TILT-123 (NCT04217473).
Keywords: adenovirus; oncolytic virus; immunotherapy; safety; biodistribution
1. Introduction
Oncolytic adenovirus therapy was approved for the treatment of advanced head and
neck cancer in China in combination with chemotherapy in 2005 [1]. Since then, several
different approaches aiming to improve treatment efficacy have been taken in clinical
phase 1 and 2 trials [2–4]. Typically, new oncolytic adenovirus product candidates carry
one or two transgenes coding for immunostimulatory agents, such as GM-CSF, CD40L, or
4-1BBL [2,5]. These approaches are further studied in combination with other treatments,
such as immune checkpoint inhibitors [6].
Oncolytic adenovirus treatments have generally been well tolerated in humans. The
typical adverse events are grades 1 and 2, including flu-like symptoms, headache, nausea,
fatigue and dizziness, anemia, leuko- and thrombocytopenia, elevated liver transaminases,
and diarrhea. Before using a new therapy on patients, it is important to evaluate the safety
in preclinical models. Syrian hamsters serve as a good preclinical model for adenovirus
product safety because it is semi-permissive for adenovirus replication, unlike mice, which
are nonpermissive [7]. Immunocompromised mice with human xenografts can, however,
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provide complementary data on the direct effects of an oncolytic virus or the transgenes on
healthy tissues.
Here, we investigate the preclinical safety and biodistribution of an oncolytic aden-
ovirus TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2). TILT-123 is a chimeric adenovirus
based on type 5 with a fiber knob from type 3, which is used to increase the tumor cell
transfection through desmoglein-2 [8,9]. The E2F promoter and the 24-base-pair (bp) dele-
tion in constant region 2 of E1A restrict viral replication to cancer cells defective for the
p16-retinoblastoma pathway. The virus codes for two transgenes: human Tumor Necrosis
Factor alpha (TNFa) and Interleukin-2 (IL-2). TILT-123 was designed to enable and enhance
T-cell therapies and immune checkpoint inhibitors in solid tumors [10]. It has shown
complete responses in animals treated in combination with tumor-infiltrating lymphocytes,
Chimeric Antigen Receptor (CAR) T cells, or immune checkpoint inhibitors anti-PD-1
and anti-PD-L1 [10–13]. Also, the use of TILT-123 has been shown to remove the need
for preconditioning chemotherapy and postconditioning IL-2, typically used in adoptive
cell therapies [14,15]. The results of this study support the initiation of a phase 1 trial,
investigating the combination of TILT-123 and tumor-infiltrating lymphocyte therapy in
melanoma (NCT04217473).
2. Materials and Methods
2.1. Animals and Treatments
A biodistribution and toxicity study was conducted in Syrian hamsters following
Good Laboratory Practices (GLP) at Cellvax S.A.S. (Paris, France). Syrian hamsters, aged
6–7 weeks males and females, were purchased from Janvier Labs (Le Genest-Saint-Isle,
France) and acclimatized for at least three days before the treatments. The animals received
six TILT-123 injections in total (days 0, 7, 21, 35, 49, and 63). The first injection was either
intravenous (i.v., retro-orbital) or intraperitoneal (i.p.). The other injections were given
i.p. The doses were diluted with 0.9% sodium chloride (sterile, i.v. quality, Laboratoires
Gilbert), which was also administered to the mock control animals (Figure 1A,B).
Hamster wellbeing was followed daily, and weight development was recorded once a
week. In addition, food and water consumption was recorded weekly. On predetermined
days, five male and female animals per group were sacrificed to collect blood, secretions
(saliva swab, urine, and feces), and organs (brain, kidneys, ovaries, testes, epididymis, liver,
prostate, uterus, heart, lungs, spleen, and vagina) for biodistribution analyses, histopathol-
ogy, blood cell analysis, and serum chemistry analyses.
Nude/NMRI female mice (Harlan Laboratories, Indianapolis, IN, USA) were accli-
matized for seven days before experimentation. Human fibrosarcoma tumors (HT-1080)
were engrafted subcutaneously and allowed to grow until 0.5 mm in diameter. The ani-
mals received 1 × 105 virus particles (VP), 1 × 107 VP, or 1 × 109 VP (corresponding to
approximately 4 × 106–4 × 1010 VP/kg) twice a week, six times in total (Figure 1C). The
first injection was given i.v. into the tail vein, and the following injections were given
intratumorally (i.t.). In addition, one group was treated with the combination of 1 × 109 VP
and 100 µg of murine anti-PD-1 (InVivoMAb anti-mouse PD-1 (CD279), BioXcell, Lebanon,
NH, USA). The control groups received saline (PBS) or anti-PD-1 alone. Anti-PD-1 admin-
istration started after two virus treatments and was given i.p. Five animals per group were
sacrificed on day 21 to collect samples (blood, heart, lung, liver, kidney, spleen, and tumor)
for virus biodistribution, toxicity, and cytokine analyses. The rest 6–7 animals/group
were left for survival experiment, where tumor growth and animal weight development
were followed.
2.2. Biodistribution
TILT-123 distribution in animals was evaluated by qPCR. A real-time TaqMan® PCR
method for TILT-123 detection and quantification in hamster tissues and biofluids was de-
veloped and validated at Accelero Bioanalycs GmbH (Berlin, Germany). The primers for de-
tecting the virus genomes in hamster tissues were designed to amplify a sequence between
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IRES and IL-2 in TILT-123, a region which does not appear in any naturally occurring naïve
specimens: forward primer CGAACCACGGGGACGTGGT; reverse primer GCAAGACT-
TAGTGCAATGCAAGACAGG; probe FAM-GATAATATGGCCACAACCATGTACAGG-
MGB. Before qPCR, an external PCR was first used to amplify the target sequence (forward
primer GCACATGCTTTACATGTGTTTAGTCGAGGT; reverse primer GAAGTAGGTG-
CACTGTTTGTGACAAGTGC). The hamster GAPDH housekeeping gene was analyzed
as a control [16]. The limit for detection was 100 VP/sample (in 200 µL), and the limit for
quantification was between 500 and 2 × 107 VP/sample.
Figure 1. Treatment schedule for TILT-123 safety studies: (A) 15 male and female hamsters received
saline or 1 × 1010, 1 × 1011, or 1 × 1012 virus particles (VP)/kg of TILT-123 six times intraperitoneally
(i.p.). Five animals/sex/group were sacrificed 3, 31, and 185 days after the first treatment. (B) Ten
male and female hamsters received saline, 1 × 1011 VP/kg, or 1 × 1012 VP/kg of TILT-123 once
intravenously (i.v.) and five times i.p. Five animals/sex/group were sacrificed 3 days after the first
injection and two weeks after the last injections (on day 77). (C) Human fibrosarcoma tumors were
implanted subcutaneously to both flanks of nude NMRI mice. Nine days after implantation, the
animals received 1 × 105 VP, 1 × 107 VP, or 1 × 109 VP i.v. The following treatments were injected
intratumorally (i.t.) Anti-PD-1 (100 µg) treatments were started on day 7 after two virus treatments.
Five animals per group were sacrificed on day 20, and the rest (6–7 animals/group) continued in the
survival study.
Mouse tissues were analyzed by detecting the 24-bp deletion region from adenovirus
E1A. Beta-acting gene expression served as a reaction control [17].
2.3. Histopathology
The collected hamster organs, except for epididymitis and testis, were fixed in 4%
formalin for at least 48 h. The epididymitis and testes were fixed in Davidson’s fluid for 48 h,
then washed, and stored in 70% ethanol at room temperature before further processing.
Mouse tissues were fixed with 10% formalin for 48 h and stored in 70% ethanol. The
tissues were embedded in paraffin wax, cut to 4-µm sections, and stained with hemalum,
or hematoxylin and eosin. Veterinary pathologists analyzed and scored the slides.
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2.4. Blood Analyses
Blood was collected by heart puncture from anesthetized or euthanized animals.
Blood cells and hemoglobin parameters were analyzed from hamster blood treated with
the K2EDTA anticoagulant. Coagulation parameters and blood chemistry were analyzed
from hamster plasma separated from the whole blood in citrate tubes or in lithium heparin,
respectively. Mouse blood was collected into dry tubes and the serum was separated by
centrifugation after blood clotting.
2.5. Neutralizing Antibodies
Ad5/3-neutralizing antibodies were analyzed from hamster serums 3 days after
i.v. injection and two weeks after the treatment period (day 77) as described before [18].
Briefly, A549 cells were infected with luciferase-expressing Ad5/3-Luc1 virus [19] mixed
with heat-treated serum samples at different dilutions (four-fold dilution series from 1:4
to 1:16384). A standard dilution series was formed from rabbit serum containing Ad5/3
neutralizing antibodies. Luciferase expression was measured with Luciferase Assay System
kit (Promega, Madison, WI, USA). The neutralizing antibody titer was determined as the
lowest degree of dilution that blocked gene transfer by >80%, as compared with the assay
condition where Ad5/3-Luc1 was not neutralized with an antiserum.
2.6. Transgene Expression
The expression of TILT-123 transgenes human TNFa and human IL-2 were analyzed
from hamster and mouse serums with human ELISA kits (Abcam, Cambridge, UK or R&D
Systems, Minneapolis, MN, USA). The serum was extracted from whole blood in dry tubes.
In addition, the transgenes were analyzed from homogenized mouse organs and tumors.
The cytokine levels in tissues were normalized against the total protein content in the
sample, measured with a Bradford assay.
2.7. Selective Replication In Vitro
Selective replication of TILT-123 was studied in A549 lung adenocarcinoma cells
(positive control, purchased from ATCC, Manassas, VA, USA), human primary hepatocytes
(Lonza Verviers SPRL, Bruxelles, Belgium), human MRC-5 fibroblasts (ATCC), and human
vascular endothelial HUVEC cells (Millipore). The cells were plated on 24-well plates
and infected with TILT-123, wild type Adenovirus 5 (VR-1516, ATCC), Ad5/3 replicative
control virus (a similar selection device as TILT-123 but no cytokine payload), or Ad5/3-
Luc1 non-replicative control virus [10,19]. Infected cells and cell culture supernatants were
harvested 72 h post-infection by centrifugation.
The virus was released from the cells by repeating freeze–thaw cycles four times in
total. DNA was extracted from the samples with the phenol/chloroform/isoamyl alcohol
(25:24:1) method and the virus copy numbers determined by detecting the adenovirus E4
copy number in samples by qPCR [20]. Infectious virus particles were determined with
TCID50 assay, where a sample dilution series was plated on A549 cells and cytopathic
effect formation was followed for ten days. TILT-123 transgene production was measured
from the cell culture supernatants with ELISA, as described above.
2.8. Statistical Analysis
Statistical analyses were performed with GraphPad Pism 8.2 using the Mann–Whitney
or ANOVA test. Tumor growth curves, animal weight development, and water and food
consumption were analyzed using linear mixed model analysis in IBM SPSS Statistics
version 24.0.0.2. A p-value smaller than 0.05 was considered significant.
3. Results
3.1. Repeated TILT-123 Injections Do Not Cause Visual Signs of Organ Damage in Hamsters
Syrian hamsters were injected six times i.p. or once i.v. and five times i.p. with
TILT-123 to investigate virus biodistribution and toxicity in a replication-permissive im-
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munocompetent model. The doses (low, mid, and high) corresponded to the ones planned
to be used in a clinical setting, ranging from 1 × 1010 VP/kg to 1 × 1012 VP/kg. Repeated
TILT-123 injections did not cause premature deaths or visual signs of organ damage in
hamsters. All hamsters had positive weight development over time, but the treatment
period caused temporary weight loss (Figure S1). The treated hamsters consumed slightly
less food but more water than the control animals, both of which are typical stress reac-
tions. Hamster weight development, and food and water consumption were similar for
the animals that received all injections i.p. and for those that were treated first i.v. and
five times i.p.
3.2. TILT-123 Induces Acute Immune Reactions in Hamsters
The highest treatment dose increased the number of leucocytes in hamster blood
only after the first virus injection (Figure 2A). This was seen especially as an increase in
neutrophil levels, which was the dominating myeloblast-derived cell population at an early
sampling point and in the middle of the treatment period (Figure 2G). At the last sampling
point (six months after the beginning of the study), the dominating myeloblast-derived cell
population was monocytes (Figure 2G). Treatments did not influence large unstained cell
levels (Figure 2C).
Figure 2. Circulating blood cell levels in hamsters: the hamsters received six TILT-123 injections i.p. at three different doses.
Leucocytes (A), lymphocytes (B), large unstained cells (C), red blood cells (D), reticulocytes (E), thrombocytes (F), and
myeloblast-derived cells (monocytes, basophils, eosinophils, and neutrophils) (G) were counted from the whole blood
at three time points (3, 31, and 185 days after the first treatment). The data show the means plus standard error of mean.
Statistical significance between the cell number in control group vs. treatment group on each time point was evaluated with
the Mann–Whitney test (* p < 0.05).
In the middle of the treatment period, the only statistically significant difference in the
blood cell populations was a slightly reduced reticulocyte level in animals treated with the
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highest dose (Figure 2E). Lymphocyte, erythrocyte, and thrombocyte levels were slightly
elevated with the highest dose at the last sampling point, and thrombocytes elevated also
with the lowest dose (Figure 2B,D,F). However, individual animal-level raw data reveal
that half of the control samples had low thrombocyte numbers (<15 Giga/L) whereas the
other half had numbers comparable to previous sampling points (>500 Giga/L).
When the first injection was given i.v., the changes in blood cells were similar as
when the injection was i.p. (Figure S3). The leucocyte levels were slightly elevated,
reflecting elevated lymphocyte, neutrophil, monocyte, and basophil levels. In addition,
treatment increased the reticulocyte levels slightly, which was also seen as slightly higher
erythrocyte levels. Treated animals had also a higher number of thrombocytes after a single
i.v. injection than the control animals, but the treatment did not affect the mean platelet
volume (Figure S4). Two weeks after the treatments stopped, the blood cell levels were
comparable between the treatment and control groups.
Blood clotting was delayed in some animals in both the treatment and the control
groups at the last sampling time point (day 185), when the animals received six i.p. in-
jections (Figure S2H,I). Increased activated, partial thromboplastin time was also seen in
samples collected two weeks after the treatment period from animals that received the
first injection i.v. and the rest i.p. (Figure S4). Prothrombin time, however, was similar
between the groups at both time points. Considering the scattered thrombocyte counts and
the phenomenon seen in both treated and control animals, a technical handling error in
sample preparation cannot be ruled out. As these findings did not clearly correlate with
treatment, they do not raise an obvious safety concern, but blood clotting is a parameter
that will, nevertheless, be closely monitored in the clinical phase.
Even though the erythrocyte level was slightly elevated with the highest dose at
the last sampling point after i.p. injections, it did not affect the red distribution width
(Figure S2B). However, hematocrit, mean corpuscular hemoglobin, and mean corpuscular
hemoglobin concentration were also slightly elevated in animals treated with the lowest
and highest doses, at the last sampling point (Figure S2C,E,F). Hemoglobin and hematocrit
levels were slightly elevated also after i.v. injection, but changes were not observed in
other parameters evaluating erythrocyte performance (Figure S4). Taken together, the data
suggests that treatment did not significantly affect erythrocytes or their performance.
3.3. TILT-123 Does Not Damage Hamster Organs
The serum chemistry analyses provided data for TILT-123 toxicity evaluation together
with histopathological analyses. A veterinary pathologist did not observe any treatment-
related abnormalities in healthy hamster tissues. Also, no major differences were observed
in the serum chemistry values between the vehicle control and treatment groups.
Compared to the control group, i.p. treatment with any dose acutely elevated aspartate
aminotransferase and total protein levels in blood (Figure 3B,F, respectively). Of note,
sample hemolysis, which was observed in some of the samples, can induce falsely high
liver enzyme and lactate dehydrogenase levels. The elevation in total protein level was
due to an elevated serum globulin level, which also led to a lower albumin-to-globulin
ratio (Figure 3H,I, respectively). At later time points, these parameters were comparable to
the control group values.
Middle and high doses also elevated the alkaline phosphatase and lactic acid dehy-
drogenase levels, respectively, on day 3. All blood values in the treatment groups were
comparable to the control group by the middle of the treatment period. At the last sampling
time point, day 185, the alanine transaminase, aspartate aminotransferase, and lactic acid
dehydrogenase levels were lower in animals treated with the lowest and highest doses
compared to the control group (Figure 3A,B,D, respectively).
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Figure 3. Blood chemistry values in hamsters: the hamsters received six i.p. TILT-123 injections at three different doses.
Alanine transaminase (A), aspartate aminotransferase (B), alkaline phosphatase (C), lactic acid dehydrogenase (D), gamma-
glutamyl transpeptidase (E), total protein level (F), serum albumin (G), and serum globulin (H) were measured from
hamster serum samples at three time points (3, 31, and 185 days after the first treatment). In addition, albumin to globulin
ratio was calculated to depict the relative amounts of these proteins in serum (I). The data show means plus standard error
of mean. Statistical significance between the molecule levels in the control group vs. treatment group on each time point
was evaluated with the Mann–Whitney test (* p < 0.05; ** p < 0.01; *** p < 0.001).
I.v. injection did not cause worse changes in blood chemistry values than i.p. in-
jections. Alanine transaminase, aspartate aminotransferase, lactic acid dehydrogenase,
total protein, and albumin levels were lower in treated animals than in control animals on
day 3 (Figure S5). Alkaline phosphatase levels were slightly elevated in treated animals
on day 3 but on the same level as the control group values two weeks after the treatments
(day 77) (Figure S5C). Like alkaline phosphatase levels, all other serum chemistry values
were comparable to the control group values two weeks after treatment, except serum
protein and albumin levels, which were slightly elevated in the treatment groups but still
close to the control animal values (Figure S5F,G).
TILT-123 transgenes human TNFa and IL-2 were also measured from hamster blood
at different time points. The levels remained mainly under the method’s lower limit of
detection, which indicates that TILT-123 was not replicating in hamsters that were not
bearing tumors (Figure 4A–F). This is expected as the virus is designed to replicate in a
tumor-specific manner.
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Figure 4. TILT-123 transgene expression and neutralizing antibodies in hamster sera: human TNFa and IL-2 were analyzed
from hamster sera by ELISA after three i.p. injections on day 31 (A,B) and after six injections at the end of the experiment
(day 185) (C,D). In addition, the transgene expression (E,F) and Ad5/3 neutralizing antibodies (G) were measured after
one i.v. injection (day 3) and two weeks after the last i.p. injection (day 77). LOD: Limit of Detection; LLOQ: Lower Limit
of Quantification.
3.4. TILT-123 Is Rapidly Cleared from Healthy Hamster Tissues
TILT-123 administration led to the formation of neutralizing antibodies during the
treatment period (Figure 4G). In one animal, a slight increase in antibody levels was
observed already 3 days after the first treatment. All samples were clearly positive two
weeks after the entire treatment regimen (day 77). The neutralizing antibodies participated
in virus clearance, which occurred in non-tumor-bearing hamsters by the middle of the
treatment period.
When TILT-123 was administered i.p., virus genomes were mainly found in the spleen
and in individual kidney, lung, blood, and gonad samples after the first injection (Figure 5).
Most of the samples were negative for the virus genomes by the middle of the treatment
period. Only one sample (a female gonad) was positive on day 185.
When TILT-123 was administered i.v., most of the virus genomes were found in
the liver and spleen after the first injection (Figure S6). Some positive samples were
also obtained from the heart, kidney, lungs, and brain. All but two kidney samples and
one lung sample were free from virus genomes two weeks after the treatment period
(day 77). Neither of the treatment routes resulted in virus shedding though saliva, urine,
or feces (Figure S7).
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Figure 5. TILT-123 biodistribution in hamsters: the hamsters received six TILT-123 injections i.p. at the dose of
1 × 1011 VP/kg. The presence of TILT-123 in hamster tissues was studied with qPCR at three time points (3, 31, and
185 days after the first treatment). Only values above the limit of quantification are shown.
3.5. The Combination of TILT-123 and Anti-PD-1 Is Well Tolerated and Has Antitumor Efficacy in
a Mouse Xenograft Study
Nude/NMRI mice bearing subcutaneous human fibrosarcoma tumors were treated
with TILT-123 monotherapy or in combination with mouse anti-PD-1. Significant tumor
growth control was seen with the combination approach (Figure 6A,B). Four out of six
animals in the combination group were cured and remained tumor-free until the end
of the experiment (day 222). Additionally, one animal was cured with the lowest virus
dose (1 × 105 VP) and with anti-PD1 alone. Of note, all cured tumors were among the
smallest 25% at the beginning of treatment, indicating that initial size might have influenced
the likelihood of a curative response. The control animals gained more weight than the
treated animals during the experimental period, but the differences were not statistically
significant (Figure 6C,D).
The virus was located mostly in tumors 48 h after the last treatment (day 20) (Figure 6E).
Regarding organs, most virus genomes were detected from livers and spleens, similar to
the findings from non-tumor-bearing hamsters. Only one serum sample from the TILT-
123-treated animals was positive for virus genome copies. Low levels of human TNFa
were also found in healthy tissues, but much higher concentrations were present in the
tumors (Figure 6F). IL-2 was only detected in tumors (Figure 6G). Treatment with the
highest TILT-123 dose with or without anti-PD-1 reduced the serum urea nitrogen levels.
All other values were comparable between the control and treatment groups (Figure 6H).
Histopathological evaluation of the hearts, spleens, lungs, livers, and kidneys did not
reveal treatment-related changes.
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Figure 6. Mice treated with TILT-123 and anti-PD-1 show tumor growth reduction. Nude mice bearing subcutaneous human
fibrosarcoma tumors received TILT-123 (black arrows) and anti-PD-1 treatments (grey arrows) twice a week. Anti-PD-1
treatments started on day 7 and were given i.p. The first virus injection was given i.v., and the rest was given i.t. Tumor
size was measured with a digital caliper (A,B), and animals were weighed (C,D) two to three times a week. Tumor size
and animal weight at the beginning of the treatment period was set to 100%. Adenovirus genomes were detected from
the tumors and healthy tissue samples (E) by qPCR and normalized against the genomic DNA amount or sample volume.
TILT-123 transgenes human TNFa (F) and human IL-2 (G) were analyzed from tumors and healthy tissue samples with
ELISA and were normalized to total protein contents in the samples. (H) Whole blood was collected from mice 48 h after
last treatment (day 20). The serum was separated after blood coagulation. The data show mean plus standard error of mean.
Statistical significance was evaluated with the log-linear mixed models analysis (tumor growth and weight development) or
with one-way ANOVA. * p < 0.05; **** p < 0.0001; Ad = TILT-123 injection; aPD1 = anti-PD-1; VP = Virus Particles.
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3.6. TILT-123 Replication Is Restricted to Cancer Cells
As some virus was observed in healthy tissues after treatments, selective replication
was studied further in vitro. Human primary hepatocytes, vascular endothelial cells,
and fibroblasts were infected with TILT-123 or the control viruses, and the presence of
physical and infectious virus particles were studied 72 h post-infection. Neither physical
nor infectious TILT-123 particles were detected in the normal cells (Figure 7A,B). However,
some TNFa and IL-2 were found from the cell culture supernatants, indicating that low
levels of transgene expression might occur in these cells in vitro even though functional
virus particles are not formed (Figure 7C,D).
Figure 7. TILT-123 replicates selectively in cancer cells in vitro. A549 lung adenocarcinoma cells,
human primary hepatocytes, MRC5 fibroblasts, and human vascular endothelial HUVEC cells were
infected with TILT-123, Ad5/3 replicative control virus (similar selection device as TILT-123 but no
cytokine payload), wild-type adenovirus type 5 (Ad5 wt), or replication-incompetent Ad5/3-Luc1
virus or left uninfected as a control (mock). (A) Virus genomes and (B) infectious virus particles were
analyzed from the infected cells 72 h after infection. TILT-123 transgenes TNFa (C) and IL-2 (D) were
analyzed from cell culture supernatants.
4. Discussion
New treatment modalities are urgently needed, especially for metastatic and recurrent
cancer. Immunotherapies provide promising results in part of this patient population, but
complete responders are still rare [21]. Response rates can be improved with combination
therapies, for example, when oncolytic viruses are combined with immune checkpoint
inhibitors [22]. As opposed to combinations of two checkpoint inhibitors, preliminary data
indicate that oncolytic virus with one checkpoint inhibitor does not seem to increase toxicity
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over single-agent treatment in humans [22]. Preclinical studies on treatment toxicities are,
nevertheless, important to perform prior to human trials.
Here, we evaluated the preclinical safety of TILT-123 as a monotherapy and in com-
bination with an immune checkpoint inhibitor anti-PD-1. Treatment doses, schemes, and
routes of administration mimic the clinical setting. Monotherapy studies were conducted
in Syrian hamsters, which allow human adenovirus replication, including chimeric 5/3
type adenoviruses [7,10]. The combination of TILT-123 and anti-PD-1 was studied in nude
mice, as a hamster anti-PD-1 has not been described to date. This model allowed TILT-123
replication in the implanted tumors and transduction of healthy tissues.
Because the hamster study included long-term follow up, it was not feasible to have
the animals bear tumors. Thus, all injections were given i.p. To compare different systemic
routes of administration, some of the hamsters received the first injection i.v. Because the
aim of the mouse study was to collect acute safety data, tumors could be engrafted and
treated i.t. after an initial i.v. treatment, as planned in the clinical setting.
The results show that TILT-123 is safe in animals when administered in clinically
relevant (and above) doses (1 × 1010–1 × 1012 VP/kg). The main difference between i.p.
and i.v. injection routes was biodistribution: i.v. administration spread the virus more
widely in the body. Virus genomes were mainly found from the spleen and gonads after
i.p. administration, whereas when given i.v., the gonads were unaffected but most of the
virus was located in the liver. The observed i.p. biodistribution profile is compatible with
direct transduction of i.p. organs, while i.v. appears to give access to the liver.
Regarding safety parameters, i.p. and i.v. administration caused similar changes in
blood cell compartments and serum chemistry. Not surprisingly, the treatment seemed to in-
crease the number of circulating leucocytes, especially lymphocytes and neutrophils, which
are typically the first cell types to emerge into the blood upon infection. The neutrophil
population was the dominating myeloblast-derived cell type during the treatment period,
but after a recovery period, the number of monocytes increased. It is likely that, during the
treatment period, monocytes differentiated into dendritic cells and macrophages as a reac-
tion to infection, which lead to a decrease in monocyte numbers. After a recovery period,
the number of monocytes was the largest compartment among myeloblast-derived cells.
The replication of TILT-123 is restricted to cancer cells by two genetic modifications: a
tumor specific promoter and a partial deletion in one of the early genes. The selectivity
seemed to hold well in vitro, as normal human cell cultures were not producing infectious
particles. Low levels of transgene expression seemed to occur, which may relate to virus
design, as transgene cassettes are in the E3 early region. Rapid clearance of the virus
from the animals, the absence of histopathological changes, and low cytokine levels in
the hamster serum indicate that the selectivity devices work well also in vivo. These
parameters will be important to monitor in the human trial.
Because TILT-123 is designed to enable T-cell therapies and immune checkpoint
inhibitors, additional safety analyses were conducted in mice in combination with anti-
PD-1. In immunocompetent animals, the combination results in a 100% survival rate [12].
Surprisingly, antitumor efficacy was observed also in immunocompromised nude/NMRI
mice, which lack most immune cell compartments. Nevertheless, the combination might
have antitumor effects through immunological reactions because the mice still possess
functional B cells, dendritic cells, macrophages, and natural killer (NK) cells. Out of
these cell compartments, anti-PD-1 could possibly induce the functionality of B cells
and NK cells.
In mice, activated NK cells express PD-1 that suppresses cell functionality when bound
to PD-L1 [23]. Regarding tumors with impaired MHC-I expression, NK cells are possibly
even more important for antitumor immune reactions than T cells. Moreover, PD-1 and
PD-L1 blockades are known to enhance the functionality of NK cells against tumors [23].
Mouse NK cells express more PD-1 when infiltrating tumors than those in the spleen,
indicating that the tumor microenvironment might induce the expression of PD-1 [23].
Similarly, human NK cells do not typically express PD-1, but ovarian cancer patients have
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exceptionally high numbers of these cells in blood and ascites [24]. Pesce et al. reported
that these cells are less proliferative and express less IL-2 and IL-15 than PD-1-negative NK
cells. Thus, stimulation of NK cells with TILT-123 and anti-PD-1 also has clinical relevance.
B cells have a controversial role in regulating antitumor efficacy: regulatory B cells
express PD-L1 and suppress T-cell functionality, but some subtypes produce antibodies and
cytokines that promote T-cell activity via dendritic cells [25,26]. B cells can also produce
granzyme B, which can kill cancer cells directly. As NMRI mice do not have a T-cell
compartment, B cells most probably had a minor role in mediating antitumor efficacy.
Nevertheless, activated B cells do express PD-1 and the PD-L1/PD-L2 blockade can induce
their activity [27]. When the interaction is blocked, these cells can proliferate more, express
activation markers, and produce more IL-6 [27]. In addition, antibody production by B
cells could in theory stimulate antibody-dependent cellular cytotoxicity mediated by NK
cells. Both antiviral and antitumor antibodies have been implicated as potentially relevant
in oncolytic immunotherapy [28].
The addition of anti-PD-1 to a TILT-123 treatment regimen did not cause additive
toxicity. As in hamsters, these treatments did not cause histological changes in mouse
normal tissues or affect serum chemistry values, even though traces of virus genomes
were found in all analyzed healthy tissues when the highest dose was used and in some
animals treated with the middle dose. However, the virus was mostly present in tumors,
where it can replicate. As human adenovirus entry into mouse tissues is restricted, using
human CD46 or desmoglein-2 (adenovirus type 3 receptors) transgenic mice might allow
greater transduction and can cause more effects on healthy tissues. In the used model,
the highest copy number levels in normal tissues were observed in the spleen and liver,
indicating a similar biodistribution as in hamsters. The results are also in accordance
with the observations of the biodistribution of other oncolytic adenoviruses [16,29–31] and
previous reports on 5/3 chimeric adenovirus that have the same capsid as TILT-123 [16,20].
Of note, as NMRI mice lack a complete immune system, any virus leaking from the tumor
to normal tissues is not cleared as efficiently as from immunocompetent animals. Thus, the
virus levels in normal tissues are expected to be even lower in subjects with a functional
immune system.
To summarize, similar safety and biodistribution profiles were seen in immuno-
competent hamsters and in immunocompromised mice. Good safety results were not
compromised when TILT-123 was combined with anti-PD-1. Overall, the data reported
here indicate that the virus does not replicate in normal tissues and that it is rapidly cleared
from nontumor organs. These data support clinical translation of TILT-123.
5. Conclusions
The study shows that repeated administration of TILT-123 is safe in animals as
monotherapy and in combination with an immune checkpoint inhibitor anti-PD-1. Acute
changes in blood values indicate that the virus induces immunological reactions in im-
munocompetent animals but that the values return to normal levels after the acute phase.
The virus is also rapidly cleared from healthy tissues, where it cannot replicate. Importantly,
the treatment did not cause any tissue-level changes in animals.
Supplementary Materials: The following are available online at https://www.mdpi.com/2073-4
409/10/2/246/s1, Figure S1: Hamster weight development, and food and water consumption: the
hamsters were weighed at least once a week. Water and food consumption were recorded regularly.
(A) The hamsters treated six times i.p. weighed less than the control animals (mean plus standard
error of mean are shown). They also consumed less food. The animals treated with high and middle
doses consumed more water than the control animals. (B) Animals that were treated first i.v. and then
i.p. weighed slightly less than the control animals (mean plus standard error of mean are shown).
The highest treatment dose induced lowered food intake but higher water intake. Also, the animals
treated with the middle dose consumed more water than the control animals. Statistical difference
was evaluated with log-ranked mixed models: ** p < 0.01; **** p < 0.0001. Figure S2: Hamster
blood values: mean platelet volume (A), red distribution width (B), hematocrit (C), hemoglobin
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(D), mean corpuscular hemoglobin (E), mean corpuscular hemoglobin concentration (F), and mean
corpuscular volume (G) were measured from whole blood at three time points (3, 31, and 185 days
after the first treatment). In addition, blood coagulation was evaluated by measuring activated partial
thromboplastin time (H) and prothrombin time (I). The data show means plus standard error of
mean. Statistical significance between the cell numbers in the control group vs. treatment group
on each time point was evaluated with the Mann–Whitney test (* p < 0.05; ** p < 0.01). Figure S3:
Hamster blood cells after one intravenous injection and five intraperitoneal injections: whole blood
was collected through heart puncture after one intravenous injection (day 3) and two weeks after
the last injection (day 77). Statistical difference was evaluated with log-ranked mixed models: *
p < 0.05; *** p < 0.001. Figure S4: Hamster blood values after one intravenous injection and five
intraperitoneal injections: whole blood was collected through heart puncture after one intravenous
injection (day 3) and two weeks after the last injection (day 77). Statistical significance between the
cell numbers in the control group vs. treatment group on each time point was evaluated with the
Mann–Whitney test (* p < 0.05; ** p < 0.01). Figure S5: Blood chemistry values in hamsters treated first
intravenously followed by five intraperitoneal treatments: alanine transaminase (ALT) (A), aspartate
aminotransferase (AST) (B), alkaline phosphatase (ALP) (C), lactic acid dehydrogenase (LDH) (D),
gamma-glutamyl transpeptidase (GGT) (E), total protein level (PROT) (F), serum albumin (ALB) (G),
and serum globulin (GLOB) (H) were measured from hamster serum samples at two time points
(3 days after the first treatment and two weeks after the last treatment on day 77). In addition, the
albumin to globulin ratio (A:G) was calculated to depict the relative amounts of these proteins in
serum (I). The data show means plus standard error of mean. Statistical significance between the
molecule levels in the control group vs. treatment group on each time point was evaluated with the
Mann–Whitney test (* p < 0.05; ** p < 0.01; **** p < 0.0001). LLOQ: Lower Limit of Quantification.
Figure S6: TILT-123 biodistribution in hamsters treated intravenously and intraperitoneally: the
presence of TILT-123 hamster tissues was studied with qPCR three days after the intravenous injection
(day 3) and two weeks after the last intraperitoneal injection (day 77). Only values above limit of
quantification are shown. Figure S7: Virus shedding after treatments: TILT-123 shedding through
saliva, urine, and feces was studied with qPCR at three time points (3, 31, and 185 days after the first
treatment) (A–C), three days after one intravenous injection (day 3, D–F), or two weeks after one
intravenous injection and five intraperitoneal injections (day 77, D–F). Only values above the limit of
quantification are shown.
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